FDA approves RYZUMVI eye drops for presbyopia treatment in adults

The U.S. FDA has approved Viatris' RYZUMVI (phentolamine ophthalmic solution 0.75%) for treating presbyopia in adults, expanding its use beyond pharmacologically-induced mydriasis. Presbyopia is an age-related condition causing difficulty focusing on near objects, affecting daily life and productivity. Viatris is seeking a U.S. partner to commercialize RYZUMVI for this new indication. The drug is generally well-tolerated with mild, temporary side effects.

Viatris (VTRS) shares are trading at USD 18.61 on Pluang as of Oct 17, 2026 03:11 WIB, showing a 1-day gain of 2.14%. This price level places the stock in a positive trend supported by a dividend yield of 2.63% and a market cap of $20.93 billion. The typical hold time of 57 days on Pluang suggests moderate investor confidence in the health sector stock amid the recent FDA approval news.